{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Alcala N"],"funding":["Associazione Italiana per la Ricerca sul Cancro","World Health Organization","Institut National Du Cancer","Ligue Nationale contre le Cancer France Genomique","Foundation for the National Institutes of Health","NCI NIH HHS"],"pagination":["3407"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6702229"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(1)"],"pubmed_abstract":["The worldwide incidence of pulmonary carcinoids is increasing, but little is known about their molecular characteristics. Through machine learning and multi-omics factor analysis, we compare and contrast the genomic profiles of 116 pulmonary carcinoids (including 35 atypical), 75 large-cell neuroendocrine carcinomas (LCNEC), and 66 small-cell lung cancers. Here we report that the integrative analyses on 257 lung neuroendocrine neoplasms stratify atypical carcinoids into two prognostic groups with a 10-year overall survival of 88% and 27%, respectively. We identify therapeutically relevant molecular groups of pulmonary carcinoids, suggesting DLL3 and the immune system as candidate therapeutic targets; we confirm the value of OTP expression levels for the prognosis and diagnosis of these dis"],"journal":["Nature communications"],"pubmed_title":["Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids."],"pmcid":["PMC6702229"],"funding_grant_id":["001","R03CA195253","IG 19238","PRT-K-17-047","TABAC 17-022","R03 CA195253"],"pubmed_authors":["Leblay N","Thomas de Montpreville V","Cuenin C","Moonen L","Pelosi G","Alcala N","Brustugun OT","Lantuejoul S","Meyer V","Blanc-Fournier C","Viari A","Ghantous A","Wright G","Voegele C","Lund-Iversen M","Roz L","Saenger J","McKay JD","Galateau-Salle F","Sandoval J","Le Calvez-Kelm F","Brevet M","Hervas D","Sertier AS","Hofman P","Brambilla E","Brcic L","Le Stang N","Deleuze JF","Speel EJM","Hofman V","Fernandez-Cuesta L","Papotti MG","Field JK","Herceg Z","Pastorino U","Vignaud JM","Gabriel AAG","Boland A","Soltermann A","Chabrier A","Ferrari A","Russell PA","Giffon T","Graziano P","Foll M","Clement JH","Lemaitre N","Boyault S","Abedi-Ardekani B","Hernandez-Vargas H","Altmuller J","Popper H","Lacomme S","Toffart AC","Durand G","Dingemans AMC","Caux C","Girard N","Stojsic J","Sozzi G","Mangiante L","Delhomme TM","Nuernberg P","Milione M","Volante M","Olaso R","Lorimier P","Derks J","Muscarella LA"],"additional_accession":[]},"is_claimable":false,"name":"Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids.","description":"The worldwide incidence of pulmonary carcinoids is increasing, but little is known about their molecular characteristics. Through machine learning and multi-omics factor analysis, we compare and contrast the genomic profiles of 116 pulmonary carcinoids (including 35 atypical), 75 large-cell neuroendocrine carcinomas (LCNEC), and 66 small-cell lung cancers. Here we report that the integrative analyses on 257 lung neuroendocrine neoplasms stratify atypical carcinoids into two prognostic groups with a 10-year overall survival of 88% and 27%, respectively. We identify therapeutically relevant molecular groups of pulmonary carcinoids, suggesting DLL3 and the immune system as candidate therapeutic targets; we confirm the value of OTP expression levels for the prognosis and diagnosis of these dis","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Aug","modification":"2026-06-04T02:12:41.041Z","creation":"2019-08-26T07:04:10Z"},"accession":"S-EPMC6702229","cross_references":{"pubmed":["31431620"],"doi":["10.1038/s41467-019-11276-9"]}}